IN188419B - - Google Patents

Info

Publication number
IN188419B
IN188419B IN3276DE1998A IN188419B IN 188419 B IN188419 B IN 188419B IN 3276DE1998 A IN3276DE1998 A IN 3276DE1998A IN 188419 B IN188419 B IN 188419B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Ulrich Niewohner
Mazen Es-Sayed
Helmut Haning
Thomas Schenke
Karl-Heinz Schlemmer
Jorg Keldenich
Erwin Bischoff
Elisabeth Perzborn
Klaus Dembowsky
Peter Serno
Marc Nowakowski
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27217917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN188419(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19750085A external-priority patent/DE19750085A1/de
Priority claimed from DE1998112462 external-priority patent/DE19812462A1/de
Priority claimed from DE1998140289 external-priority patent/DE19840289A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of IN188419B publication Critical patent/IN188419B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IN3276DE1998 1997-11-12 1998-11-05 IN188419B (US06559137-20030506-C00039.png)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19750085A DE19750085A1 (de) 1997-11-12 1997-11-12 2-Phenyl-substituierte Imidazotriazinone
DE1998112462 DE19812462A1 (de) 1998-03-23 1998-03-23 2-[2-Ethoxy-5(4-ethyl-piperazin-1-sulfonyl) -phenyl]-5-methyl-7-prophyl-3H-imidazo[5,1-f][1,2,4]triazin-4-on Dihydrochlorid
DE1998140289 DE19840289A1 (de) 1998-09-04 1998-09-04 2-Phenyl-substituierte Imidazotriazinone

Publications (1)

Publication Number Publication Date
IN188419B true IN188419B (US06559137-20030506-C00039.png) 2002-09-21

Family

ID=27217917

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3276DE1998 IN188419B (US06559137-20030506-C00039.png) 1997-11-12 1998-11-05

Country Status (44)

Country Link
US (9) US6362178B1 (US06559137-20030506-C00039.png)
EP (3) EP1049695B1 (US06559137-20030506-C00039.png)
JP (2) JP3356428B2 (US06559137-20030506-C00039.png)
KR (2) KR100430355B1 (US06559137-20030506-C00039.png)
CN (2) CN100430396C (US06559137-20030506-C00039.png)
AR (2) AR013759A1 (US06559137-20030506-C00039.png)
AT (1) ATE213246T1 (US06559137-20030506-C00039.png)
AU (1) AU738675B2 (US06559137-20030506-C00039.png)
BG (1) BG65257B1 (US06559137-20030506-C00039.png)
BR (2) BR9812785A (US06559137-20030506-C00039.png)
CA (2) CA2395558C (US06559137-20030506-C00039.png)
CH (1) CH693954A5 (US06559137-20030506-C00039.png)
CO (1) CO4980861A1 (US06559137-20030506-C00039.png)
CU (1) CU23063A3 (US06559137-20030506-C00039.png)
CY (1) CY1112949T1 (US06559137-20030506-C00039.png)
CZ (1) CZ301911B6 (US06559137-20030506-C00039.png)
DE (3) DE59803108D1 (US06559137-20030506-C00039.png)
DK (3) DK1049695T3 (US06559137-20030506-C00039.png)
EE (1) EE04781B1 (US06559137-20030506-C00039.png)
ES (3) ES2386420T3 (US06559137-20030506-C00039.png)
FI (1) FI113772B (US06559137-20030506-C00039.png)
GB (1) GB2346877B (US06559137-20030506-C00039.png)
HK (2) HK1031730A1 (US06559137-20030506-C00039.png)
HN (1) HN1998000175A (US06559137-20030506-C00039.png)
HR (2) HRP20000292B1 (US06559137-20030506-C00039.png)
HU (3) HU228196B1 (US06559137-20030506-C00039.png)
ID (1) ID25871A (US06559137-20030506-C00039.png)
IL (3) IL135462A0 (US06559137-20030506-C00039.png)
IN (1) IN188419B (US06559137-20030506-C00039.png)
LU (1) LU90561B1 (US06559137-20030506-C00039.png)
MY (1) MY138535A (US06559137-20030506-C00039.png)
NO (2) NO314940B1 (US06559137-20030506-C00039.png)
NZ (1) NZ504436A (US06559137-20030506-C00039.png)
PE (1) PE131799A1 (US06559137-20030506-C00039.png)
PL (2) PL201336B1 (US06559137-20030506-C00039.png)
PT (2) PT1174431E (US06559137-20030506-C00039.png)
SE (1) SE522809C2 (US06559137-20030506-C00039.png)
SI (2) SI1049695T1 (US06559137-20030506-C00039.png)
SK (1) SK287161B6 (US06559137-20030506-C00039.png)
TR (1) TR200001338T2 (US06559137-20030506-C00039.png)
TW (2) TWI229081B (US06559137-20030506-C00039.png)
UA (1) UA46166C2 (US06559137-20030506-C00039.png)
UY (2) UY25246A1 (US06559137-20030506-C00039.png)
WO (1) WO1999024433A1 (US06559137-20030506-C00039.png)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
UA46166C2 (uk) * 1997-11-12 2002-05-15 Баєр Акцієнгезельшафт 2-фенілзаміщені імідазотриазинони як інгібітори фосфодіестерази, спосіб їх одержання та лікарський засіб на їх основі
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
DE19944161A1 (de) * 1999-09-15 2001-03-22 Bayer Ag Neue Kombination zur Behandlung von sexueller Dysfunktion
CA2323008C (en) 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
IL139454A0 (en) * 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
US20040254153A1 (en) * 1999-11-08 2004-12-16 Pfizer Inc Compounds for the treatment of female sexual dysfunction
JP2003519151A (ja) 1999-12-24 2003-06-17 バイエル アクチェンゲゼルシャフト トリアゾロトリアジノンおよびそれらの使用
PL356848A1 (en) * 1999-12-24 2004-07-12 Bayer Aktiengesellschaft Novel imidazo[1,3,5]triazinones and the use thereof
JP2003519153A (ja) 1999-12-24 2003-06-17 バイエル アクチェンゲゼルシャフト イソオキサゾロピリミジノン類及びその使用
DE10010067A1 (de) * 2000-03-02 2001-09-06 Bayer Ag Neue Imidazotriazinone und ihre Verwendung
DE60124085D1 (de) 2000-04-19 2006-12-07 Lilly Icos Llc Pde-v hemmer zur behandlung von morbus parkinson
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
CA2423305A1 (en) * 2000-09-29 2002-04-04 Glaxo Group Limited Compounds useful in the treatment of inflammatory diseases
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
DE10063106A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur Herstellung von 2-(2-Ethoxyphenyl)-substituierten Imidazotriazinonen
DE10063108A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur Herstellung von Sulfonamid-substituierten Imidazotriazinonen
DE10064105A1 (de) 2000-12-21 2002-06-27 Bayer Ag Neue Substituierte Imidazotriazinone
BR0206847A (pt) * 2001-02-02 2004-02-25 Pfizer Tratamento do diabete melito
DE10107639A1 (de) * 2001-02-15 2002-08-22 Bayer Ag 2-Alkoxyphenyl-substituierte Imidazotriazinone
DE10108752A1 (de) 2001-02-23 2002-09-05 Bayer Ag Neue Substituierte Imidazotriazinone
GB0107751D0 (en) * 2001-03-28 2001-05-16 Pfizer Ltd Pharmaceutically active compounds
DE10118306A1 (de) 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
CA2449163C (en) * 2001-05-09 2010-07-13 Bayer Healthcare Ag New use of 2-phenyl-substituted imidazotriazinones
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7087605B2 (en) 2001-06-01 2006-08-08 Bayer Aktiengesellschaft 5-Ethyl-imidazotriazinones
GB0113344D0 (en) * 2001-06-01 2001-07-25 Bayer Ag Novel heterocycles 3
DE10130167A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
EP1421084B1 (en) 2001-08-28 2008-05-14 Schering Corporation Polycyclic guanine phosphodiesterase v inhibitors
CA2465893A1 (en) * 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
HU228316B1 (en) * 2001-12-13 2013-03-28 Daiichi Sankyo Company Pyrazolopyrimidinone derivatives having pde7-inhibitory activity
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
GB0209988D0 (en) * 2002-05-01 2002-06-12 Bayer Ag Novel Heterocycles
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
AU2003265239A1 (en) 2002-05-22 2003-12-19 Virginia Commonwealth University Protective effects of pde-5 inhibitors
WO2003099194A2 (en) * 2002-05-23 2003-12-04 Pfizer Limited Pharmaceutical combination of pde5 inhibitors with ace inhibitors
SI1509525T1 (sl) 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
DE10230605A1 (de) 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
JP2006511606A (ja) 2002-12-13 2006-04-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 下部尿路症状を治療するα−2−δリガンド
EP1608656B1 (en) 2003-04-01 2009-06-03 SmithKline Beecham Corporation Imidazotriazine compounds for the treatment of cancer diseases
AU2004234158B2 (en) 2003-04-29 2010-01-28 Pfizer Inc. 5,7-diaminopyrazolo[4,3-D]pyrimidines useful in the treatment of hypertension
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
CA2526475A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
JP2006528229A (ja) 2003-05-22 2006-12-14 アルタナ ファルマ アクチエンゲゼルシャフト Pde4阻害剤及びpde5阻害剤を含有する組成物
CN100374441C (zh) 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2,3-d]嘧啶-4-酮衍生物,其制备方法及其制药用途
JP2006219374A (ja) * 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するイミダゾトリアジノン誘導体
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
AR047948A1 (es) * 2003-11-21 2006-03-15 Schering Corp Formulaciuones de inhibidores de la fosfodiesterasa v
US7572799B2 (en) * 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
GB0327323D0 (en) * 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
BRPI0506994A (pt) 2004-01-22 2007-07-03 Pfizer derivados de triazol que inibem a atividade antagonista da vasopressina
JP2007532526A (ja) * 2004-04-07 2007-11-15 ファイザー・インク ピラゾロ[4,3−d]ピリミジン類
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
JP2008501617A (ja) * 2004-06-11 2008-01-24 アスビオファーマ株式会社 Pde7阻害作用を有するイミダゾトリアジノン誘導体
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
UA90502C2 (ru) * 2005-02-18 2010-05-11 Сьёрфейс Лоджикс, Инк. Имидазотриазиноновые соединения и фармацевтическая композиция, которая их содержит
US20110172422A1 (en) * 2005-02-18 2011-07-14 Surface Logix, Inc. Methods of Making Pharmacokinetically Improved Compounds Comprising Functional Residues or Groups and Pharmaceutical Compositions Comprising Said Compounds
DE102005009241A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005016345A1 (de) * 2005-04-09 2006-10-12 Bayer Healthcare Ag Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
EP1874309A1 (en) 2005-04-19 2008-01-09 Nycomed GmbH Roflumilast for the treatment of pulmonary hypertension
WO2006120552A2 (en) 2005-05-12 2006-11-16 Pfizer Inc. ANHYDROUS CRYSTALLINE FORMS OF N-[1-(2-ETHOXYETHYL)-5-(N-ETHYL-N-METHYLAMINO)-7-(4-METHYLPYRIDIN-2-yl-AMINO)-1H-PYRAZOLO[4,3-d]PYRIMIDINE-3-CARBONYL]METHANESULFONAMIDE
WO2006127368A2 (en) * 2005-05-20 2006-11-30 Lexicon Genetics Incorporated Methods for synthesizing imidazotriazinones
US20070010525A1 (en) * 2005-06-27 2007-01-11 Meyer Jackson Method and compositions for modulating neuropeptide hormone secretion
JP2009504628A (ja) * 2005-08-10 2009-02-05 ファイザー・リミテッド オキシトシン拮抗薬としての置換トリアゾール誘導体
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス,インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
AU2006299232A1 (en) * 2005-09-29 2007-04-12 Bayer Schering Pharma Aktiengesellschaft PDE inhibitors and combinations thereof for the treatment of urological disorders
US20070093493A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US7687666B2 (en) * 2006-02-17 2010-03-30 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
PE20080109A1 (es) * 2006-02-17 2008-04-01 Wyeth Corp N-sulfonilacion selectiva de alcoholes sustituidos con 2-aminotrifluoralquilo
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7977478B2 (en) * 2006-03-13 2011-07-12 Dr. Reddy's Laboratories Limited Polymorphic forms of vardenafil
DK2489350T3 (en) * 2006-03-17 2014-03-03 Univ Johns Hopkins Med N-hydroxylsulfonamidderivater as new physiologically useful nitroxyldonorer
WO2007124045A2 (en) * 2006-04-20 2007-11-01 Ampla Pharmaceuticals, Inc. Piperidine and piperazine compounds for use in the treatment of obesity, eating disorders and sexual dysfunction by potentiation of mc4 receptor activity
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2008000418A2 (en) 2006-06-27 2008-01-03 Sandoz Ag New method for salt preparation
WO2008008398A2 (en) * 2006-07-14 2008-01-17 Shionogi & Co., Ltd. Oxime compounds and the use thereof
CA2661483A1 (en) * 2006-08-24 2008-02-28 Surface Logix, Inc. Pharmacokinetically improved 2-phenyl-substituted imidazotriazinone derivatives and their use
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
DE102006043443A1 (de) * 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
HUE025355T2 (en) 2006-12-12 2016-02-29 Gilead Sciences Inc Composition for treating pulmonary hypertension
PL2114147T3 (pl) * 2007-02-12 2012-10-31 Vyrix Pharmaceuticals Inc Zmniejszanie skutków ubocznych tramadolu
AU2008216356C1 (en) * 2007-02-12 2014-07-24 Aytu Bioscience, Inc. Treatment of comorbid premature ejaculation and erectile dysfunction
WO2008100886A1 (en) * 2007-02-12 2008-08-21 Auspex Pharmaceuticals, Inc. Preparation and use of deuterated udenafil analogues as highly selective pde5 modulators for the treatment of erectile dysfunction
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
DE102007027067A1 (de) * 2007-06-12 2008-12-18 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Vardenafil Hydrochlorid Trihydrat
WO2008151734A1 (en) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of hearing impairment
WO2009030095A1 (en) * 2007-09-06 2009-03-12 Topharman Shanghai Co., Ltd. Process for preparing vardenafil and its intermediates
ES2388371T3 (es) 2007-12-28 2012-10-15 Topharman Shanghai Co., Ltd. N-{1-[3-(2-etoxi-5-(4-etilpiperazinil)bencenosulfonil)-4,5-dihidro-5-oxo-1,2,4-triazin-6-il]etil}-butiramida, método de preparación y uso
US20090181975A1 (en) * 2008-01-15 2009-07-16 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
DE102009020888A1 (de) 2009-05-12 2010-11-18 Ratiopharm Gmbh Schmelztablette, enthaltend ein Vardenafil-Salz
EP2462127A1 (en) 2009-08-07 2012-06-13 Ranbaxy Laboratories Limited Processes for the preparation of vardenafil
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
TR201816146T4 (tr) 2009-11-27 2018-11-21 Adverio Pharma Gmbh Meti̇l-{4,6-di̇ami̇no-2-[1-(2-florobenzi̇l)-1h-pi̇razolo[3,4-b]pi̇ri̇di̇n-3-i̇l]pi̇ri̇mi̇di̇n-5-i̇lmeti̇l}karbamatin farmasöti̇k etken madde olarak kullanima yöneli̇k olarak üreti̇lmesi̇ne yöneli̇k yöntem.
EP2517705B1 (en) 2009-12-21 2016-10-19 Acef S/A Cubebin as vasodilating agent in the therapy of erectile dysfunction
PL390079A1 (pl) * 2009-12-30 2011-07-04 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób otrzymywania wardenafilu i jego izolacji jako soli z kwasem cytrynowym oraz krystaliczna postać tej soli
EP2556820A4 (en) 2010-04-05 2015-01-21 Sk Chemicals Co Ltd COMPOSITION CONTAINING PDE5 INHIBITOR FOR MITIGATION OF SKIN WRINKLES
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CN102382129B (zh) * 2010-08-19 2014-02-26 山东轩竹医药科技有限公司 螺环取代的磷酸二酯酶抑制剂
CN102372730B (zh) * 2010-08-19 2014-03-26 山东轩竹医药科技有限公司 桥环取代的磷酸二酯酶抑制剂
ES2610360T3 (es) 2010-09-20 2017-04-27 Ironwood Pharmaceuticals, Inc. Compuestos de imidazotriazinona
BR112013005434A2 (pt) 2010-09-23 2016-06-07 Abbott Lab novo mono-hidrato de derivados de aza-adamantano
RS56135B1 (sr) 2010-10-15 2017-10-31 Gilead Sciences Kompozicije i metode za lečenje plućne hipertenzije
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Sildenafil-同族物四級銨哌嗪鹽類之製備及醫療用途
CN102134242B (zh) * 2011-01-21 2013-08-28 浙江大德药业集团有限公司 一种用于治疗阳痿的快速长效的化合物
CA2886885C (en) 2011-10-10 2019-07-16 H. Lundbeck A/S Pde9i with imidazo pyrazinone backbone
AT512084A1 (de) 2011-10-20 2013-05-15 Univ Wien Tech Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
CZ303877B6 (cs) * 2011-11-24 2013-06-05 Zentiva, K.S. Zpusob prípravy a izolace solí vardenafilu s kyselinami
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2013109738A1 (en) 2012-01-17 2013-07-25 The Trustees Of Columbia University In The City Of New York Novel phosphodiesterase inhibitors and uses thereof
US9434733B2 (en) 2012-01-26 2016-09-06 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone
CA2864322C (en) 2012-02-28 2016-08-09 Seoul Pharma. Co., Ltd. High-content fast dissolving film with masking of bitter taste comprising sildenafil as active ingredient
WO2013142269A1 (en) 2012-03-19 2013-09-26 Envivo Pharmaceuticals, Inc. Imidazotriazinone compounds
CN103374002B (zh) * 2012-04-19 2015-07-15 山东轩竹医药科技有限公司 磷酸二酯酶-5抑制剂
CZ307091B6 (cs) 2012-09-14 2018-01-10 Zentiva, K.S. Stabilní farmaceutický přípravek obsahující Vardenafil hydrochlorid
KR102146673B1 (ko) 2012-12-04 2020-08-21 주식회사 아리바이오 포스포디에스테라제 타입 5 저해제를 포함하는 신경세포의 아폽토시스 억제용 조성물
KR101953735B1 (ko) 2012-12-14 2019-03-04 한미약품 주식회사 포스포다이에스터라제-5 억제제를 포함하는 츄정
EA201500852A1 (ru) 2013-02-21 2016-02-29 Адверио Фарма Гмбх Формы метил {4,6-диамино-2-[1-(2-фторбензил)-1н-пиразоло[3,4-в]пиридино-3-ил]пиримидино-5-ил}метил карбамата
CN104109164B (zh) * 2013-04-18 2016-05-25 广州朗圣药业有限公司 一种适合工业化的高纯度盐酸伐地那非三水合物的制备方法
EP3022205B1 (en) 2013-07-17 2020-02-05 The Trustees of Columbia University in the City of New York Novel phosphodiesterase inhibitors and uses thereof
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
PL223869B1 (pl) 2013-12-16 2016-11-30 Starogardzkie Zakłady Farm Polpharma Spółka Akcyjna Sposób otrzymywania wardenafilu i jego soli
KR101645652B1 (ko) 2014-11-03 2016-08-08 (주)퓨젠바이오농업회사법인 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물
SI3865484T1 (sl) 2015-07-07 2024-05-31 H. Lundbeck A/S Zaviralec pde9 z imidazo pirazinonsko hrbtenico za zdravljenje perifernih bolezni
US10570137B2 (en) 2015-11-16 2020-02-25 Topadur Pharma Ag 2-phenyl-3,4-dihydropyrrolo[2,1 -F] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CA3046025A1 (en) 2016-12-14 2018-06-21 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
EP3630769A1 (en) 2017-05-22 2020-04-08 Topadur Pharma AG Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
CN107445964A (zh) * 2017-07-29 2017-12-08 合肥创新医药技术有限公司 一种盐酸伐地那非杂质的合成方法
JP2021506986A (ja) 2017-12-20 2021-02-22 クラリア・ファルマ・ホールディング・アクチボラグ バルデナフィルを含むフィルム配合物、その調製法、およびその使用
JP2021526134A (ja) 2018-05-25 2021-09-30 イマラ インク. 6−[(3S,4S)−4−メチル−l−(ピリミジン−2−イルメチル)ピロリジン−3−イル]−3−テトラヒドロピラン−4−イル−7H−イミダゾ[l,5−A]ピラジン−8−オンの一水和物および結晶形態
JP2021527267A (ja) 2018-06-14 2021-10-11 アストラゼネカ・ユーケイ・リミテッドAstraZeneca UK Limited Cgmp特異的ホスホジエステラーゼ5阻害剤の薬学的組成物により勃起不全を治療するための方法
CN112955967A (zh) 2018-06-14 2021-06-11 阿斯利康(英国)有限公司 用cgmp特异性磷酸二酯酶5抑制剂医药组合物治疗勃起功能障碍的方法
MX2021005892A (es) * 2018-11-28 2021-06-23 Topadur Pharma Ag Novedosos activadores de guanilato ciclasa soluble e inhibidores de fosfodiesterasa con modo de accion dual y usos de estos.
WO2020184670A1 (ja) 2019-03-13 2020-09-17 大塚製薬株式会社 二級アミンを含有する化合物のアミン部分に重水素低級アルキルを導入する方法
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
AR124199A1 (es) 2020-12-11 2023-02-22 Ildong Pharmaceutical Co Ltd Nuevos compuestos como inhibidor dual del receptor de andrógenos y de la fosfodiesterasa
CN114085225A (zh) * 2021-06-04 2022-02-25 广东西捷药业有限公司 一种伐地那非类似物及其合成方法和应用
JP2024536047A (ja) 2021-09-29 2024-10-04 トパデュール ファルマ アーゲー 2-フェニル-3,4-ジヒドロピロロ[2,l-f][1,2,4]トリアジノン誘導体の局所組成物及びその使用
IL314241A (en) 2022-03-02 2024-09-01 Topadur Pharma Ag Local preparations and their uses
KR20230129639A (ko) 2022-03-02 2023-09-11 연세대학교 산학협력단 이중작용 pde5 억제제/질산유기에스터의 국소 혈류 증진을 위한 경피 투약 형태
WO2024173675A1 (en) 2023-02-16 2024-08-22 University Of Rochester Improving glymphatic-lymphatic efflux

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US26565A (en) * 1859-12-27 Improved register for railroad-cars
DE812845C (de) 1944-12-07 1951-09-06 Georges Lissac Brille
US2705715A (en) 1952-10-29 1955-04-05 American Cyanamid Co Purine compounds and methods of preparing the same
CH367510A (de) 1957-11-27 1963-02-28 Ciba Geigy Verfahren zur Herstellung neuer Sulfonamide
GB1042471A (en) 1963-01-16 1966-09-14 Ilford Ltd Penta-azaindenes, their production and use in photographic emulsions
GB1051734A (US06559137-20030506-C00039.png) 1963-01-16
US3169129A (en) 1963-05-10 1965-02-09 American Cyanamid Co 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones
USRE26565E (en) 1966-03-02 1969-04-29 Table iii
GB1338235A (en) 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
GB1493685A (en) 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
BE791025A (fr) * 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques
GB1457873A (en) * 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
US4052390A (en) 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
US4060615A (en) 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
GB1561345A (en) 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4159330A (en) 1976-11-02 1979-06-26 Carlo Erba S.P.A. 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
GB1584461A (en) 1977-03-25 1981-02-11 Allen & Hanburys Ltd Imidazotriazines imidazotriazinones and pharmaceutical compositions containing them
US4308384A (en) 1978-09-18 1981-12-29 Glaxo Group Limited Production of triazinones
US4287673A (en) * 1980-01-11 1981-09-08 Sunbeam Corporation Hair dryer diffuser
EP0054132B1 (de) 1980-12-12 1984-10-10 Dr. Karl Thomae GmbH Neue Pyrimidinone, ihre Herstellung und Arzneimittel mit einem Gehalt an diesen Stoffen
US4431440A (en) 1981-02-20 1984-02-14 American Cyanamid Company Method to alter or control the development and/or the life cycle of various plant species
JPS60246396A (ja) 1984-05-22 1985-12-06 Sankyo Co Ltd 酵素阻害物質ジヒドロデスオキシグリゼオ−ル酸及びその塩類
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
CA1303037C (en) 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
US5254571A (en) 1988-04-21 1993-10-19 Smith Kline & French Laboratories Ltd. Chemical compounds
GB8814352D0 (en) 1988-06-16 1988-07-20 Smith Kline French Lab Chemical compounds
ES2058527T3 (es) 1988-06-16 1994-11-01 Smith Kline French Lab Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US4923874A (en) 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
US5574020A (en) * 1989-09-28 1996-11-12 Eli Lilly And Company Tilmicosin formulation
GB8928346D0 (en) 1989-12-15 1990-02-21 Smith Kline French Lab Chemical compounds
EP0524180B1 (en) * 1990-04-11 1995-04-26 The Upjohn Company Taste masking of ibuprofen by fluid bed coating
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5316906A (en) 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
GB9119704D0 (en) * 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) * 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en) 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9312210D0 (en) 1993-06-14 1993-07-28 Smithkline Beecham Plc Chemical compounds
GB9315017D0 (en) 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
US5614627A (en) 1993-09-10 1997-03-25 Eisai Co., Ltd. Quinazoline compounds
US5374053A (en) * 1994-01-21 1994-12-20 Heidelberger Druckmaschinen Ag Device for changing the transport position of products
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9612514D0 (en) * 1996-06-14 1996-08-14 Pfizer Ltd Novel process
UA46166C2 (uk) 1997-11-12 2002-05-15 Баєр Акцієнгезельшафт 2-фенілзаміщені імідазотриазинони як інгібітори фосфодіестерази, спосіб їх одержання та лікарський засіб на їх основі
US6221402B1 (en) * 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
CA2323008C (en) * 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
PL356848A1 (en) * 1999-12-24 2004-07-12 Bayer Aktiengesellschaft Novel imidazo[1,3,5]triazinones and the use thereof
CA2449163C (en) 2001-05-09 2010-07-13 Bayer Healthcare Ag New use of 2-phenyl-substituted imidazotriazinones
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel

Also Published As

Publication number Publication date
HU227841B1 (en) 2012-05-02
DK1049695T3 (da) 2002-05-13
US6890922B2 (en) 2005-05-10
PL340400A1 (en) 2001-01-29
AU1558799A (en) 1999-05-31
ES2386420T3 (es) 2012-08-20
ES2194567A1 (es) 2003-11-16
ES2194567B1 (es) 2005-03-01
IL135462A (en) 2006-04-10
CN1508137A (zh) 2004-06-30
BR9816155B1 (pt) 2010-07-27
AR035972A2 (es) 2004-07-28
SE0001745D0 (sv) 2000-05-11
US20130059844A1 (en) 2013-03-07
HN1998000175A (es) 1999-01-08
JP2001522851A (ja) 2001-11-20
EE200000291A (et) 2001-06-15
EP1174431B1 (de) 2012-05-30
EP2295436A1 (de) 2011-03-16
US7122540B2 (en) 2006-10-17
DE19881732D2 (de) 2000-08-24
NO314940B1 (no) 2003-06-16
GB2346877A (en) 2000-08-23
JP2002348290A (ja) 2002-12-04
ID25871A (id) 2000-11-09
CA2395558A1 (en) 1999-05-20
SK287161B6 (sk) 2010-02-08
HRP20020585B1 (hr) 2013-02-28
NO20002444L (no) 2000-05-11
UY25671A1 (es) 2000-03-31
TW513431B (en) 2002-12-11
HUP0100394A2 (hu) 2001-09-28
ES2172945T3 (es) 2002-10-01
TR200001338T2 (tr) 2000-08-21
HU228196B1 (en) 2013-01-28
US7704999B2 (en) 2010-04-27
IL135462A0 (en) 2001-05-20
KR100548120B1 (ko) 2006-02-02
DK176852B1 (en) 2009-12-14
LU90561B1 (de) 2000-12-01
NO20021714D0 (no) 2002-04-11
BG104406A (en) 2001-08-31
HRP20000292B1 (en) 2008-09-30
BR9812785A (pt) 2000-10-10
SE0001745L (sv) 2000-05-11
DK200000766A (da) 2000-05-09
PL201336B1 (pl) 2009-03-31
ATE213246T1 (de) 2002-02-15
EP1049695B1 (de) 2002-02-13
EP1049695A1 (de) 2000-11-08
US7696206B2 (en) 2010-04-13
CN1123573C (zh) 2003-10-08
JP4388729B2 (ja) 2009-12-24
FI113772B (fi) 2004-06-15
EP1174431A2 (de) 2002-01-23
CU23063A3 (es) 2005-07-19
GB0010974D0 (en) 2000-06-28
US20050070541A1 (en) 2005-03-31
US6566360B1 (en) 2003-05-20
MY138535A (en) 2009-06-30
US20060189615A1 (en) 2006-08-24
SK7092000A3 (en) 2001-03-12
AR013759A1 (es) 2001-01-10
CO4980861A1 (es) 2000-11-27
PT1049695E (pt) 2002-07-31
HK1067124A1 (en) 2005-04-01
DK1174431T3 (da) 2012-08-20
US6362178B1 (en) 2002-03-26
NO20002444D0 (no) 2000-05-11
DE19881732C1 (de) 2002-01-31
UA46166C2 (uk) 2002-05-15
HRP20000292A2 (en) 2001-04-30
GB2346877B (en) 2001-12-05
HUP0100394A3 (en) 2002-05-28
HK1031730A1 (en) 2001-06-22
CY1112949T1 (el) 2016-04-13
DE59803108D1 (de) 2002-03-21
KR100430355B1 (ko) 2004-05-04
TWI229081B (en) 2005-03-11
SI1174431T1 (sl) 2012-09-28
CN100430396C (zh) 2008-11-05
US20110009367A1 (en) 2011-01-13
CH693954A5 (de) 2004-05-14
CA2395558C (en) 2007-07-17
BG65257B1 (bg) 2007-10-31
HRP20020585A2 (en) 2005-10-31
CN1278822A (zh) 2001-01-03
PT1174431E (pt) 2012-07-24
CA2309332A1 (en) 1999-05-20
HU230154B1 (hu) 2015-09-28
AU738675B2 (en) 2001-09-20
WO1999024433A1 (de) 1999-05-20
JP3356428B2 (ja) 2002-12-16
UY25246A1 (es) 2001-08-27
CA2309332C (en) 2002-12-03
CZ301911B6 (cs) 2010-07-28
US20100016323A1 (en) 2010-01-21
US7314871B2 (en) 2008-01-01
US20080113972A1 (en) 2008-05-15
CZ20001759A3 (cs) 2000-10-11
US20040067945A1 (en) 2004-04-08
SI1049695T1 (en) 2002-06-30
EE04781B1 (et) 2007-02-15
NO20021714L (no) 2000-05-11
SE522809C2 (sv) 2004-03-09
KR20010031944A (ko) 2001-04-16
IL163475A (en) 2015-11-30
EP1174431A3 (de) 2002-01-30
PL194801B1 (pl) 2007-07-31
FI20001086A (fi) 2000-05-09
KR20040014591A (ko) 2004-02-14
NZ504436A (en) 2001-08-31
PE131799A1 (es) 1999-12-30

Similar Documents

Publication Publication Date Title
BE2018C032I2 (US06559137-20030506-C00039.png)
IN188419B (US06559137-20030506-C00039.png)
IN188411B (US06559137-20030506-C00039.png)
CH0944937H2 (US06559137-20030506-C00039.png)
ITMI971064A0 (US06559137-20030506-C00039.png)
BE2013C047I2 (US06559137-20030506-C00039.png)
ITVI970055A0 (US06559137-20030506-C00039.png)
ITMI971220A0 (US06559137-20030506-C00039.png)
BR9701757A (US06559137-20030506-C00039.png)
IN188732B (US06559137-20030506-C00039.png)
IN191986B (US06559137-20030506-C00039.png)
IN192432B (US06559137-20030506-C00039.png)
ITMI970507V0 (US06559137-20030506-C00039.png)
BR9700653A (US06559137-20030506-C00039.png)
CN3055713S (US06559137-20030506-C00039.png)
CN3056875S (US06559137-20030506-C00039.png)
CN3054556S (US06559137-20030506-C00039.png)
CN3054902S (US06559137-20030506-C00039.png)
CN3055123S (US06559137-20030506-C00039.png)
CN3055179S (US06559137-20030506-C00039.png)
CN3055389S (US06559137-20030506-C00039.png)
CN3055471S (US06559137-20030506-C00039.png)
CN3055519S (US06559137-20030506-C00039.png)
CN3055603S (US06559137-20030506-C00039.png)
CN3054099S (US06559137-20030506-C00039.png)